Astellas Pharma Europe Limited
Acronym: APEL
General Information
Identification Code: 726065718920-12
Website: [object Object]
Entity Form: Corporation
Registration Category: Companies & groups
Registration Date: 9/24/2015
Last Update: 4/22/2024
EP Accredited Number: 2
Mission & Interests
Goals: At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater value by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Business and industry
- Competition
- Consumers
- Customs
- Economy, finance and the euro
- Employment and social affairs
- Enlargement
- Environment
- External relations
- Institutional affairs
- International co-operation and development
- Public health
- Regional policy
- Research and innovation
- Taxation
- Trade
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: Intellectual Property Rights and incentives - including Orphan Medicinal Products, Paediatric medicines
Free Trade Agreements - EU/US, EU/UK,
EU Beating Cancer Plan,
EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes,
Industrial strategy,
Competition law,
Horizon Europe,
Innovative Health Initiative (IHI),
European Medicines Agency (EMA),
European Health Data Space (EHDS)
Committee of the Regions,
Clinical Trials Regulation,
Data Protection Regulation,
Digital health,
Community code related to medicinal products for human use in mainly countries that are part of the European Union - General Pharma Legislation
Other policy areas of interest include Manufacturing, Health outcomes, Real world evidence, Pricing, reimbursement and market access to medicines, cancer, healthcare sustainability, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.
Communication Activities: We are a member of the European Federation of Pharmaceutical Industries and Associations and its Oncology platform. We are also member of the Alliance for Regenerative Medicines.
We are participating in events on industrial, health and life science policy.
We are meeting with policy makers in the EU institutions and engaging with other public policy stakeholders.
We are funding and participating in a campaign called Let's Talk Prostate Cancer, and are engaged in a roundtable on Combination Therapies and on Bladder Cancer.
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Bourne Business Park300 Dashwood Lang Road
Post Code: KT15 2NX
City: Addlestone
Country: UNITED KINGDOM
Phone: [object Object]
EU Office
Address: Bourne Business Park300 Dashwood Lang Road
Post Code: KT15 2NX
City: Addlestone
Country: UNITED KINGDOM
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: RPP is running our Let's Talk Prostate Cancer campaign in which we reach out to policymakers.
Membership Information
Members10 Percent: 0
Members25 Percent: 1
Members50 Percent: 0
Members75 Percent: 1
Members: 2
Members F T E: 1
Structure
Structure Type: Structure
Is Member Of: Alliance for Regenerative Medicines
EFPIA
Organisation Members: EFPIA
Alliance for Regenerative Medicines